| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8214739 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 29 Pages |
Abstract
Patients with pT4 or N1 disease have a 2-year risk of LF that exceeds 30%. These patients may be the most likely to benefit from local adjuvant therapies.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Abhinav V. BA, Joseph J. MD, Shane M. MD, Ralph R. MD, Norm D. MD, Gary D. MD, Stanley L. MD,